Incidence of Dyschromatopsia in Glaucoma

NCT ID: NCT02966678

Last Updated: 2017-06-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-08

Study Completion Date

2017-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Incidence of dyschromatopsia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Incidence of dyschromatopsia should be elevated in glaucoma compared to a healthy control population. However, the actual incidence rate is not investigated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glaucoma

Patients with a diagnosis of glaucoma will undergo color vision test

Color Vision Test

Intervention Type PROCEDURE

Farnsworth Panel D15/Hue test plus Ishihara charts

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Color Vision Test

Farnsworth Panel D15/Hue test plus Ishihara charts

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of glaucoma
* age between 18 and 99 years old
* best corrected visual acuity(BCVA) \> 0.2 (decimal Snellen)

Exclusion Criteria

* age \< 18 yo
* BCVA \< 0.2
* known dyschromatopsia
* known corneal disease
* St.p. corneal surgeries
* macula disease
* history of medication use that can influence color vision (e.g. hydroxychloroquine)
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jens Funk, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

UniversityHospital Zurich, Dept. of Ophthalmology

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dyschromatopsia

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.